A virtual reality-based task could help differentiate people with Alzheimer’s disease from the normal cognitive impairment that occurs with age, according to a pilot study
Eisai and Biogen now have their second regulatory approval for anti-amyloid therapy Leqembi – in Japan – as a treatment for slowing the progression of Alzheimer’s disease.
Researchers think they have worked out how neurons die off in Alzheimer's disease, a question that has gone unanswered for decades, opening new avenues for research and a
Eisai has been steadily building up expertise in the use of digital health systems to support people with dementia but has now gone one step further – launching a dedicate
Biotech Sunbird Bio has announced its completed merger with Glympse Bio, which it is hoped will accelerate development of the companies’ protein-based diagnostic technolog
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.